| scholarly article | Q13442814 |
| P2093 | author name string | A R Casey | |
| K D Ethans | |||
| R J Bard | |||
| M P Namaka | |||
| P2860 | cites work | Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. | Q50764223 |
| Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. | Q53155089 | ||
| Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. | Q53194715 | ||
| The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
| Quality of life of persons with urinary incontinence: development of a new measure. | Q53633525 | ||
| Distribution and colocalization of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable human urinary bladder | Q66829337 | ||
| Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients | Q68331136 | ||
| Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results | Q74206910 | ||
| Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? | Q79369835 | ||
| Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity | Q79400222 | ||
| Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients | Q81394349 | ||
| Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 | ||
| The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study | Q84579296 | ||
| Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder—To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial | Q85205665 | ||
| Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis | Q95480937 | ||
| The health and life priorities of individuals with spinal cord injury: a systematic review | Q27026471 | ||
| Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach | Q28742444 | ||
| Intravesical capsaicin for treatment of detrusor hyperreflexia | Q33731214 | ||
| Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. | Q33915263 | ||
| OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity | Q37536741 | ||
| Antimuscarinic drugs: review of the cognitive impact when used to treat overactive bladder in elderly patients. | Q37879017 | ||
| A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury | Q37988148 | ||
| Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder | Q38460499 | ||
| Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial | Q42670357 | ||
| Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial | Q43123491 | ||
| Health problems of persons with spinal cord injury living in the Netherlands | Q43825003 | ||
| P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin. | Q44971837 | ||
| Targeting recovery: priorities of the spinal cord-injured population | Q46083590 | ||
| Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results | Q46349100 | ||
| Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity | Q46586297 | ||
| Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. | Q46644837 | ||
| Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study | Q47379554 | ||
| The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results | Q47616169 | ||
| European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity | Q47892069 | ||
| OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity | Q48303526 | ||
| Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity | Q48389748 | ||
| Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 | ||
| Clean, intermittent self-catheterization in the treatment of urinary tract disease. 1972. | Q48729887 | ||
| Prognostic value of urodynamic testing in myelodysplastic patients. 1981. | Q48731198 | ||
| Multiple sclerosis: prevalence and factors impacting bladder and bowel function in an Australian community cohort | Q48975523 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | botulinum toxin type A | Q4095199 |
| P304 | page(s) | 65-75 | |
| P577 | publication date | 2014-03-18 | |
| P1433 | published in | Degenerative neurological and neuromuscular disease | Q27724416 |
| P1476 | title | Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA | |
| P478 | volume | 4 |
Search more.